{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:47:29Z","timestamp":1782910049029,"version":"3.54.5"},"reference-count":95,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antithrombotic therapy is a cornerstone of contemporary cardiovascular management, substantially reducing thrombotic complications across a wide spectrum of cardiovascular conditions. However, the application of antithrombotic strategies in routine clinical practice remains challenging. Many patients commonly encountered in real-world settings\u2014including elderly individuals, patients with multimorbidity, active malignancy, or advanced chronic kidney disease\u2014are underrepresented in randomized clinical trials. Consequently, current guideline recommendations, although evidence-based, may not fully capture the complexity of these populations. In daily practice, clinicians are often required to balance competing risks of thrombosis and bleeding in patients characterized by multiple comorbidities, polypharmacy, and varying degrees of frailty, particularly when more than one indication for antithrombotic therapy coexists, such as atrial fibrillation in patients undergoing percutaneous coronary intervention. In this critical narrative review, we address key high-risk scenarios\u2014frailty, advanced chronic kidney disease, active cancer, and atrial fibrillation in patients undergoing recent percutaneous coronary intervention\u2014where standard antithrombotic strategies require special consideration. We critically appraise the limitations of existing bleeding risk scores and propose practical considerations for tailoring dual antiplatelet therapy duration, minimizing triple therapy, selecting antithrombotic combinations, and reassessing risk over time to optimize net clinical benefit.<\/jats:p>","DOI":"10.3390\/jcm15135110","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"5110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines"],"prefix":"10.3390","volume":"15","author":[{"given":"Francesco Antonio","family":"Veneziano","sequence":"first","affiliation":[{"name":"Department of Cardiology, AULSS 6 Euganea, 35043 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-1272","authenticated-orcid":false,"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Giallauria, F., Di Lorenzo, A., Venturini, E., Pacileo, M., D\u2019Andrea, A., Garofalo, U., Delucia, F., Testa, C., Cuomo, G., and Vigorito, C. (2021). Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081696"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e029588","DOI":"10.1161\/JAHA.123.029588","article-title":"Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings from the EXTEND-DAPT Study","volume":"12","author":"Faridi","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000001112","article-title":"Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement from the American Heart Association","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacasi.2025.05.017","article-title":"Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy","volume":"5","author":"Chang","year":"2025","journal-title":"JACC Asia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2021.11.015","article-title":"Validation of the academic research consortium high bleeding risk criteria in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis of 10 studies and 67,862 patients","volume":"347","author":"Silverio","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12350-020-02441-5","article-title":"Beyond traditional cardiovascular risk factors: Could frailty and other morbidities explain the worse prognosis in patients undergoing pharmacologic stress?","volume":"29","author":"Bourque","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Perone, F., Bernardi, M., Spadafora, L., Betti, M., Cacciatore, S., Saia, F., Fogacci, F., Jaiswal, V., Asher, E., and Paneni, F. (2025). Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12050171"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e042767","DOI":"10.1161\/JAHA.125.042767","article-title":"Bleeding Risk with Combining Antiplatelets and Anticoagulants for Secondary Stroke Prevention: A Propensity Score-Matched Analysis","volume":"14","author":"Farrokh","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31083\/j.rcm2508281","article-title":"Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review","volume":"25","author":"Galanti","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40119-026-00444-w","article-title":"Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies","volume":"15","author":"Bauer","year":"2026","journal-title":"Cardiol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1489008","DOI":"10.1155\/2024\/1489008","article-title":"Assessing the Utility of the DAPT Score and PRECISE-DAPT Score in Determining the Appropriateness of Dual Antiplatelet Therapy in Patients With Acute Myocardial Infarction\/Percutaneous Coronary Intervention","volume":"2024","author":"Singh","year":"2024","journal-title":"Cardiol. Res. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjcard.2024.03.022","article-title":"PRECISE-DAPT, ARC-HBR, or Simplified Clinical Evaluation for the Prediction of Major Bleeding After Percutaneous Coronary Intervention in older Patients","volume":"219","author":"Marschall","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.amjcard.2018.08.025","article-title":"Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy","volume":"122","author":"Ko","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","article-title":"External validity of the PRECISE-DAPT score in patients undergoing PCI: A systematic review and meta-analysis","volume":"9","author":"Montalto","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14779072.2025.2520827","article-title":"Bleeding risk assessment tools for patients with myocardial infarction: A comparative review and clinical implications","volume":"23","author":"Thiruchelvam","year":"2025","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_23","first-page":"441","article-title":"Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE","volume":"9","author":"Price","year":"2020","journal-title":"Interv. Cardiol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14796678.2025.2599666","article-title":"Optimizing risks and benefits of dual antiplatelet therapy after ACS: A winding path to precision","volume":"22","author":"Landi","year":"2026","journal-title":"Future Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1159\/000528561","article-title":"Frailty: Pathophysiology, Theoretical and Operational Definition(s), Impact, Prevalence, Management and Prevention, in an Increasingly Economically Developed and Ageing World","volume":"69","author":"Doody","year":"2023","journal-title":"Gerontology"},{"key":"ref_27","first-page":"3111840","article-title":"Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review","volume":"2022","author":"Lacy","year":"2022","journal-title":"J. Interv. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jgs.12700","article-title":"Alterations in platelet function during aging: Clinical correlations with thromboinflammatory disease in older adults","volume":"62","author":"Mohebali","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sciahbasi, A., Minardi, S., Salvi, N., Infusino, F., and Granatelli, A. (2025). Antithrombotic Therapy in the Elderly with Cardiovascular Disease: Walking the Tightrope Between Efficacy and Bleeding Risk-A Narrative Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14207340"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00380-023-02276-3","article-title":"Association of preoperative clinical frailty and clinical outcomes in elderly patients with stable coronary artery disease after percutaneous coronary intervention","volume":"38","author":"Shimono","year":"2023","journal-title":"Heart Vessel."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.jcin.2018.08.028","article-title":"The Association of Frailty with In-Hospital Bleeding Among Older Adults with Acute Myocardial Infarction: Insights from the ACTION Registry","volume":"11","author":"Dodson","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10557-019-06911-y","article-title":"Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study","volume":"33","author":"Pavasini","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Qian, Y., Xu, B., Qian, X., Cao, L., Cheng, Y., Liu, X., Bai, S., Han, Z., and Wang, J. (2021). Incidence and Risk Factors for Antiplatelet Therapy-Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.661619"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e244000","DOI":"10.1001\/jamanetworkopen.2024.4000","article-title":"Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis","volume":"7","author":"Park","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Saeed, Z., Sirolli, V., Bonomini, M., Gallina, S., and Renda, G. (2024). Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168705"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.31083\/j.rcm2302049","article-title":"Acute coronary syndrome and renal impairment: A systematic review","volume":"23","author":"Fiorentini","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2215\/CJN.04100321","article-title":"Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy","volume":"17","author":"Baaten","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: From guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_39","unstructured":"Haysom, R., Aziz, N., Swan, D., and Thachil, J. (2025). Bleeding in Patients with Renal Impairment: A Current Perspective. Semin. Thromb. Hemost., Published online."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ekir.2023.01.012","article-title":"Association Between CKD and Major Hemorrhage in Older Persons: Data from the Aspirin in Reducing Events in the Elderly Randomized Trial","volume":"8","author":"Mahady","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00109-021-02037-7","article-title":"Vascular pathologies in chronic kidney disease: Pathophysiological mechanisms and novel therapeutic approaches","volume":"99","author":"Zietzer","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"36522","DOI":"10.31083\/RCM36522","article-title":"Antiplatelet Therapy in Heart Disease","volume":"26","author":"Ozyuncu","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Parul, F., Ratnani, T., Subramani, S., Bhatia, H., Ashmawy, R.E., Nair, N., Manchanda, K., Anyagwa, O.E., Kaka, N., and Patel, N. (2025). Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review. Healthcare, 13.","DOI":"10.3390\/healthcare13121373"},{"key":"ref_44","first-page":"CD008834","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_45","first-page":"e95538","article-title":"Prevalence of Chronic Myocardial Ischemia and Gastrointestinal Bleeding Risk in Patients with Chronic Kidney Disease Undergoing Dual Antiplatelet Therapy","volume":"17","author":"Israr","year":"2025","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/rth2.12188","article-title":"Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: More than just bleeding?","volume":"3","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/s41598-022-10164-5","article-title":"Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status","volume":"12","author":"Calderon","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cereda, A., Lucreziotti, S., Franchina, A.G., Laricchia, A., De Regibus, V., Conconi, B., Carl\u00e0, M., Spangaro, A., Rocchetti, M., and Ponti, L. (2023). Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients. Cancers, 15.","DOI":"10.3390\/cancers15092574"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1093\/eurheartj\/ehae463","article-title":"Bleeding risk prediction after acute myocardial infarction-integrating cancer data: The updated PRECISE-DAPT cancer score","volume":"45","author":"Dafaalla","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Po\u00e9nou, G., Tol\u00e9dano, E., Helfer, H., Plaisance, L., Happe, F., Versini, E., Diab, N., Djennaoui, S., and Mah\u00e9, I. (2023). Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1132156"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehaf1002","article-title":"Venous thromboembolism and bleeding in cancer patients: Role of inflammatory and cardiac biomarkers","volume":"47","author":"Roy","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12959-025-00795-9","article-title":"Cancer-Associated Thrombosis (CAT); mechanisms and treatment options","volume":"23","author":"Alshehri","year":"2025","journal-title":"Thromb. J."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ilari, A., Abbate, M.I., Verso, M., Graziani, M., Cafaro, P., Sala, L., Colonese, F., Cortinovis, D.L., and Canova, S. (2026). Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27041874"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1055\/a-2605-9015","article-title":"Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort","volume":"126","author":"Vedovati","year":"2026","journal-title":"Thromb. Haemost."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100116","DOI":"10.1016\/j.bvth.2025.100116","article-title":"Risk factors for anticoagulant-related bleeding in cancer: Traditional and cancer-specific factors","volume":"3","author":"Loncharich","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_56","first-page":"8547","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1007\/s00277-025-06482-z","article-title":"Immunotherapy-associated hemostatic abnormalities: Bleeding and thrombotic complications","volume":"104","author":"Li","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: A comprehensive review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"Mariani","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tcm.2022.02.003","article-title":"Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism","volume":"33","author":"Giustozzi","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"oeaf137","DOI":"10.1093\/ehjopen\/oeaf137","article-title":"Prediction of major bleeding events for patients with dual antiplatelet therapy after myocardial infarction-a validation of the PRECISE-DAPT cancer score","volume":"5","author":"Mamas","year":"2025","journal-title":"Eur. Heart J. Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e013000","DOI":"10.1161\/CIRCINTERVENTIONS.122.013000","article-title":"Risk Burden of Cancer in Patients Treated with Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials","volume":"17","author":"Campos","year":"2024","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcin.2021.03.049","article-title":"Cancer Patients Have a Higher Risk of Thrombotic and Ischemic Events After Percutaneous Coronary Intervention","volume":"14","author":"Guo","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100169","DOI":"10.1016\/j.tru.2024.100169","article-title":"How to manage anticoagulation for cancer-associated thrombosis and atrial fibrillation in cancer","volume":"15","author":"Tufano","year":"2024","journal-title":"Thromb. Update"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tsigkas, G., Vakka, A., Apostolos, A., Bousoula, E., Vythoulkas-Biotis, N., Koufou, E.-E., Vasilagkos, G., Tsiafoutis, I., Hamilos, M., and Aminian, A. (2023). Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10040135"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week","volume":"43","author":"Agewall","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and long-term antithrombotic therapy in older adults: 2022 update by the ESC Working Group on Thrombosis","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kessler, A., Kolben, Y., Puris, G., Ellis, M., Alperin, M., Simovich, V., Lerman Shivek, H., Muszkat, M., Maaravi, Y., and Biton, Y. (2023). Direct Oral Anticoagulants in Special Patient Populations. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010216"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Nusrat, S., Khan, S., Beg, K., and Raskob, G. (2026). Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27041756"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.18773\/austprescr.2025.009","article-title":"The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion","volume":"48","author":"Ziser","year":"2025","journal-title":"Aust. Prescr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e038589","DOI":"10.1161\/JAHA.124.038589","article-title":"Contemporary use and clinical significance of initial triple versus double therapy after percutaneous coronary intervention for myocardial infarction in patients with atrial fibrillation","volume":"14","author":"Park","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jcin.2024.10.032","article-title":"Discordance and Performance of the ARC-HBR and PRECISE-DAPT High Bleeding Risk Definitions After Coronary Stenting","volume":"18","author":"Lim","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/a-2347-6507","article-title":"Bleeding Risk in Patients with Cancer","volume":"45","author":"Englisch","year":"2025","journal-title":"Hamostaseologie"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sen, L., Kangpin, X., and Yihui, L. (2025). Research progress on bleeding risk assessment models in anticoagulant therapy. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1645823"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_86","first-page":"3258","article-title":"The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"Simon","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijcard.2016.07.268","article-title":"Frailty predicts major bleeding within 30 days in elderly patients with Acute Coronary Syndrome","volume":"222","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2020.11.065","article-title":"Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores","volume":"328","author":"Montalto","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Dong, L., Lu, C., Wensen, C., Fuzhong, C., Khalid, M., Xiaoyu, D., Guangjuan, L., Yanxia, Q., Yufeng, Z., and Xinjian, L. (2022). Performance of PRECISE-DAPT and Age-Bleeding-Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.910805"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132925","DOI":"10.1016\/j.ijcard.2024.132925","article-title":"Accurate prediction of bleeding risk after coronary artery bypass grafting with dual antiplatelet therapy: A machine learning model vs. the PRECISE-DAPT score","volume":"421","author":"Yang","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e029900","DOI":"10.1161\/JAHA.123.029900","article-title":"Dynamic Prognosis Prediction for Patients on DAPT After Drug-Eluting Stent Implantation: Model Development and Validation","volume":"13","author":"Li","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Qian, Y., Wanlin, L., and Maofeng, W. (2024). Machine learning derived model for the prediction of bleeding in dual antiplatelet therapy patients. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1402672"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:01:56Z","timestamp":1782907316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":95,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135110"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135110","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}